ReviewBone marrow transplantation2008
Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.
Review in Bone marrow transplantation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Trial
- Review
- Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.Transplantation and cellular therapy · 2021Article
- Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.Scientific reports · 2020Article
- Healthcare utilization and financial impact of acute-graft-versus host disease among children undergoing allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2020Article
- Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Adults.Einstein (Sao Paulo, Brazil) · 2020Article
- The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia.Blood advances · 2019Article
- Article
- Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection.Frontiers in immunology · 2017Review
- Alternative donor transplant of benign primary hematologic disorders.Bone marrow transplantation · 2015Review
- Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors?Current hematologic malignancy reports · 2015Review
- The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT.Bone marrow transplantation · 2014Article
- The outcomes of family haploidentical hematopoietic stem cell transplantation in hematologic malignancies are not associated with patient age.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2011Article
- Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD.Bone marrow transplantation · 2010Article
- Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.Nature reviews. Cancer · 2010Review
- Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Second hematopoietic stem cell transplantation in myeloid malignancies.Current opinion in hematology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Hematopoietic SCT from a partially HLA-mismatched (HLA-haploidentical) first-degree relative offers the benefits of rapid and near universal donor availability but also the risks that result from traversing the HLA barrier; namely, graft failure, severe GVHD and prolonged immunodeficiency. Improvements over the last 10 years in conditioning regimens, graft engineering and pharmacological immunoprophylaxis of GVHD have substantially reduced the morbidity and mortality of HLA-haploidentical SCT. Highly immunosuppressive but nonmyeloablative conditioning extends the availability of HLA-haploidentical SCT to elderly hematologic malignancy patients lacking HLA-matched donors and permits recovery of autologous hematopoiesis in the event of graft failure. Current regimens for HLA-haploidentical SCT are associated with a 2-year non-relapse mortality of 20+/-5%, relapse of 35+/-15% and overall survival of 50+/-20%. Major developmental areas include harnessing natural killer cell alloreactivity to reduce the risk of disease relapse and improving immune reconstitution by delayed infusions of lymphocytes selectively depleted of alloreactive cells. Hematologic malignancy patients who lack suitably matched related or unrelated donors can now be treated with HLA-haploidentical related donor or unrelated umbilical cord blood SCT. Future clinical trials will assess the relative risks and benefits of these two graft sources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.